Evidence map›Paper›PMID 17765528›Full record

ReviewLancet (London, England)2007

COPD exacerbations: defining their cause and prevention.

Jadwiga A Wedzicha, Terence A R Seemungal

4 registry-linked trialsAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Lancet (London, England), 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 604 papers, 14 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
604citing papers in PubMed, 14 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02268708 completednot on this mapstarted 2014, after this paper: background citation

Evaluation of Post-operative Respiratory Complications After Thoracic Surgery in Patients With COPD

TypeobservationalSponsorHôpital CochinRan2014 to 2016Enrolled100ConditionsCOPD, Malignant Neoplasm of ThoraxArmsOncological pulmonary resection
NCT03259022 unknown statusnot on this mapstarted 2016, after this paper: background citation

Bronchial Infection in Patients With COPD and Frequent Exacerbations; Role of Innate Immunity and the Use of an Electronic Nose for Diagnosis.

TypeobservationalSponsorFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauRan2016 to 2019Enrolled50ConditionsPulmonary Disease, Chronic Obstructive
NCT05315674 unknown statusnot on this mapstarted 2022, after this paper: background citation

Early Diagnostic BioMARKers in Exacerbations of COPD: the MARKED Study

TypeobservationalSponsorCenter of Expertise for Chronic Organ FailureRan2022 to 2025Enrolled150ConditionsCOPD, COPD ExacerbationArmsFrequent assessment of biomarker panel
NCT05506865 phase4completednot on this mapstarted 2012, after this paper: background citation

Efficacy and Safety of Indacaterol vs Tiotropium From Baseline to 24 Weeks, in Women With Moderate-severe COPD Secondary to Biomass Exposure: Randomized, Non Inferior, Open Label, Parallel Groups Clinical Trial

TypeinterventionalSponsorNational Institute of Respiratory Diseases, MexicoRan2012 to 2016Enrolled73ConditionsCOPDArmsIndacaterol, Tiotropium
3 · Its place in the literature

Who cites it

604 citing papers in PubMed, 14 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Short-term sleep benefitsFrontiers in pharmacology · 2026
    Pooled it
  5. Predictors of Acute Exacerbations in COPD: A Systematic Review.International journal of chronic obstructive pulmonary disease · 2026
    Pooled it
  6. Efficacy of Biologics in Patients with Moderate to Very Severe COPD: A Systematic Review.International journal of chronic obstructive pulmonary disease · 2026
    Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

544 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jadwiga A WedzichaAcademic Unit of Respiratory Medicine, Royal Free and University College Medical School; University College London, UK. j.a.wedzicha@medsch.ucl.ac.uk
Terence A R Seemungal

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Exacerbations of chronic obstructive pulmonary disease (COPD) are episodes of worsening of symptoms, leading to substantial morbidity and mortality. COPD exacerbations are associated with increased airway and systemic inflammation and physiological changes, especially the development of hyperinflation. They are triggered mainly by respiratory viruses and bacteria, which infect the lower airway and increase airway inflammation. Some patients are particularly susceptible to exacerbations, and show worse health status and faster disease progression than those who have infrequent exacerbations. Several pharmacological interventions are effective for the reduction of exacerbation frequency and severity in COPD such as inhaled steroids, long-acting bronchodilators, and their combinations. Non-pharmacological therapies such as pulmonary rehabilitation, self-management, and home ventilatory support are becoming increasingly important, but still need to be studied in controlled trials. The future of exacerbation prevention is in assessment of optimum combinations of pharmacological and non-pharmacological therapies that will result in improvement of health status, and reduction of hospital admission and mortality associated with COPD.

Indexed as

Adrenal Cortex HormonesBacterial InfectionsBronchodilator AgentsExerciseHospitalizationHumansPhosphodiesterase InhibitorsPulmonary Disease, Chronic ObstructiveRandomized Controlled Trials as TopicSeverity of Illness IndexAdrenal Cortex HormonesBronchodilator AgentsPhosphodiesterase Inhibitors

Identifiers

PMID17765528
PMCPMC7134993

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.